Диссертация (1140039), страница 12
Текст из файла (страница 12)
N Engl J Med 2008; 359(2): 158–165.82.Hodsman G.P., Phillips P.A., Ogawa K., Johnston CI. Atrial natriuretic factor innormal man: effects of tilt, posture, exercise and haemorrhage. J Hypertens Suppl1986; 4(6): S503-S505.83.Huang C.L., Lewicki J., Johnson L.K., Cogan M.G. Renal mechanism of action ofrat atrial natriuretic factor. J Clin Invest 1985; 75(2): 769-773.84.Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP,Brenner BM (1983) Role for intrarenal mechanisms in the impaired salt excretionof experimental nephrotic syndrome.
J Clin Invest 71:91–10385.Jamieson J.D., Palade G.E. Specific granules in atrial muscle cells. J Cell Biol1964; 23: 151-172.86.Joffy S., Rosner M.H. Natriuretic Peptides in ESRD. Am J Kidney Dis 2005;46(1): 1-10.87.John S.W., Krege J.H., Oliver P.M. et al. Genetic decreases in atrial natriureticpeptide and salt-sensitive hypertension.
Science 1995; 267(5198): 679-681.88.Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: amechanistic viewpoint. Kidney Int 2008; 74:22–3689.Kangawa K., Matsuo H. Purification and complete amino acid sequence of alphahuman atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys ResCommun 1984; 118(1): 131-139.8990.Koh G.Y., Klug M.G., Field L.J. Atrial natriuretic factor and transgenic mice.Hypertension 1993; 22(4): 634-639.91.Kohse K., Feifel K., Mayer-Wehrstein R. Differential regulation of brain and atrialnatriuretic peptides in hemodialysis patients. Clin Nephrol 1993; 40(2): 83-90.92.Koller P.T., Grekin R.J., Nicklas J.M.
Paradoxical response of plasma atrialnatriuretic hormone to pericardiocentesis in cardiac tamponade. Am J Cardiol1987; 59(5): 491-492.93.Komatsu Y., Nakao K., Suga S. et al. C-Type natriuretic peptide (CNP) in rats andhumans. Endocrinology 1991; 129(2): 1104-1106.94.Kleta R, Bockenhauer D (2006) Bartter syndromes and other salt-losingtubulopathies. Nephron Physiol 104:73–8095.Kleyman TR, Myerburg MM, Hughey RP (2006) Regulation of ENaCs byproteases: an increasingly complex story. Kidney Int 70:1391–139296.Klein Janet D. Corin: an ANP protease that may regulate sodium reabsorption innephrotic syndrome 1Kidney International (2010) 78, 635 – 63797.Lai C.P., Egashira K., Tashiro H.
et al. Beneficial effects of atrial natriureticpeptide on exercise-induced myocardial ischemia in patients with stable effortangina pectoris. Circulation 1993; 87(1): 144–151.98.Lee C.Y., Chen H.H., Lisy O. et al. Pharmacodynamics of a novel designernatriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. JClin Pharmacol 2009; 49(6): 668-673.99.Lenz W., Herten M., Gerzer R., Drummer C. Regulation of natriuretic peptide(urodilatin) release in a human kidney cell line.
Kidney Int 1999; 55(1): 91-99.90100.Lisy O., Huntley B.K., McCormick D.J. et al. Design, synthesis, and actionsof a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52(1):60–68.101.Lau DH, Mikhailidis DP, Thompson CS. The effect of vardenafil (a PDEtype 5 inhibitor) on renal function in the diabetic rabbit:a pilot study.
In Vivo 2007;21: 851–854102.Luss H., Mitrovic V., Seferovic P.M. et al. Renal effects of ularitide inpatients with decompensated heart failure. Am Heart J 2008; 155(6): 1012 e1–8.103.Lecomte J, Juchmes J (1978) So-called absence of edema in analbuminemia.Rev Med Liege 33:766–770104.Lau DH, Mikhailidis DP, Thompson CS. The effect of vardenafil (a PDEtype 5 inhibitor) on renal function in the diabetic rabbit:a pilot study.
In Vivo 2007;21: 851–854105.Mantymaa P., Vuolteenaho O., Marttila M., Ruskoaho H. Atrial stretchinduces rapid increase in brain natriuretic peptide but not in atrial natriureticpeptide gene expression in vitro. Endocrinology 1993; 133: 1470–1473.106.McCullough P.A., Duc P., Omland T. et al. B-type natriuretic peptide andrenal function in the diagnosis of heart failure: An analysis from the Breathing NotProperly Multinational Study.
AmJ Kidney Dis 2003; 41(3): 571–579.107.McKie P.M., Cataliotti A., Huntley B.K. et al. A human atrial natriureticpeptide gene mutation reveals a novel peptide with enhanced blood pressurelowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol2009; 54(11): 1024-1032.91108.Misono K.S., Fukumi H., Grammer R.T., Inagami T. Rat atrial natriureticfactor: complete amino acid sequence and disulfide linkage essential for biologicalactivity. Biochem Biophys Res Commun 1984; 119(2): 524-529.109.Mitaka C., Hirata Y., Habuka K. et al.
Atrial natriuretic peptide improvespulmonary gas exchange by reducing extravascular lung water in canine modelwith oleic acid-induced pulmonary edema. Crit Care Med 2002; 30(7): 1570-1575.110.Nakao K., Itoh H., Suga S. et al. The natriuretic peptide family. Curr OpinNephrol Hypertens 1993; 2(1): 45-50.111.Plum J., Y. Mirzaian and B. Grabensee. Atrial natriuretic peptide, sodiumretention, and proteinuria in nephrotic Syndrome Nephrol Dial Transplant 11:1034-1042,1996112.Pan S., Chen H.H., Dickey D.M.
et al. Biodesign of a renalprotective peptidebased on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U SA 2009; 106(27): 11282–11287.113.Pedersen E.B., Pedersen H.B., Jensen K.T. Pulsatile secretion of atrialnatriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci 1999;97(2): 201-206.114.Plum J., Grabensee B.
Atrial natriuretic peptide in dialysis patients patientsunder various conditions of volume homeostasis. J Intern Med 1991; 229(3): 209216.115.Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48:20–3292116.Rodriguez-Iturbe B, Ferrebuz A, Vanegas V et al. Early treatment withcGMP phosphodiesterase inhibitor ameliorates progression of renal damage.Kidney Int 2005; 68: 2131–2142117.Schweitz H., Vigne P., Moinier D.
et al. A new member of the natriureticpeptide family is present in the venom of the green mamba (Dendroaspisangusticeps). J Biol Chem 1992; 267(20): 13928–13932.118.Silver M.A., Maisel A., Yancy C.W. et al. BNP Consensus Panel 2004: Aclinical approach for the diagnostic, prognostic, screening, treatment monitoring,and therapeutic roles of natriuretic peptides in cardiovascular diseases. CongestHeart Fail 2004; 10: 1-30.119.Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV,Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is criticallyinvolved in the hypotensive and hypovolemic actions of atrial natriuretic peptide.
JClin Invest 2005;115:1666—74.120.Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptidein porcine brain. Nature 1988; 332(6159): 78-81.121.Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide(CNP): a new member of natriuretic peptide family identified in porcine brain.Biochem Biophys Res Commun 1990; 168(2): 863-870.122.Suresh M., Farrington K.
Natriuretic peptides and the dialysis patient. SeminDial 2005; 18(5): 409-419.123.Swärd K., Valsson F., Sellgren J., Ricksten S.E. Differential effects ofhuman atrial natriuretic peptide and furosemide on glomerular filtration rate andrenal oxygen consumption in humans. Intensive Care Med 2005; 31(1): 79-85.93124.Soo Wan Kim et al, Pathogenesis of edema in nephrotic Syndrome: role ofepithelial sodium channel Nephrology, 2007;12;S 8-10125.Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP,Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendelsohn ME. Regulatorof G-protein signaling-2 mediates vascular smooth muscle relaxation and bloodpressure. Nat Med 2003;9:1506—12.126.Usberti M, Gazzotti RM, Poiesi C, D’Avanzo L, Ghielmi S (1995)Considerations on the sodium retention in nephrotic syndrome.
Am J Nephrol15:38–47127.Valentin J.P., Humphreys M.H. Urodilatin: a paracrine renal natriureticpeptide. Semin Nephrol 1993; 13(1): 61-70.128.Vogel M.W., Chen H.H. Novel natriuretic peptides: new compounds andnew approaches. Curr Heart Fail Rep 2011; 8(1): 22-27.129.Wolf G, Butzmann U, Wenzel UO. The renin–angiotensin system andprogression of renal disease: from hemodynamics to cell biology. Nephron Physiol2003; 93: P3–P13130.Wei C.M., Kim C.H., Miller V.M., Burnett J.C.Jr.
Vasonatrin peptide: aunique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92(4):2048–2052.131.Wen Chen,1 Birgit Gaßner,1 Sebastian Börner Atrial natriuretic peptideenhancesmicrovascularalbuminpermeabilitybytranscellular pathway. Cardiovasc Res. 2012 January 1thecaveolae-mediated94132.Yandle T.G. Biochemistry of natriuretic peptides. J Intern Med 1994; 235(6):561-576.133.Zhao HJ, Wang S, Cheng H et al.
Endothelial nitric oxide synthasedeficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol2006; 17: 2664–2669.